Abstract
(VCAM-1) and E-selectin [5] . In the presence of specific chemotactic signals, such as stem cell factor (SCF) and eotaxin [6] , the mast cell precursors migrate into tissues using as sensors of chemotaxis different chemokine receptors, such as CXCR2, CCR3, CXCR4 and CCR5 [7] . Recently, the expression of transcription factor T-bet by dendritic cells has been shown to regulate the homing of mast cell precursors [8] .
In the tissues, the proliferation and differentiation of mast cell precursors depend on the presence of local growth factors and cytokines, notably SCF, IL-3, IL-4, IL-6, IL-9 and NGF [9-12], which are secreted by various tissue cells. The crucial requirement of a functional SCF and c-kit signaling system for mast cell growth and development is underscored by the fact that lack of c-kit signaling in mice results
in mast cell deficiency [13] [14] [15] , whereas an elevated expression of c-kit in patients induces mastocytosis [16, 17] [19] . [62, 63] .
. Similarly, injection of SCF into the skin of human beings results in local accumulation of mast cells [18]. Depending on the site of tissue infiltration, the precursor cells proliferate and differentiate either into connective tissue-type or mucosal-type mast cells, two well-described subsets of mast cells that differ in the quality and quantity of their stored mediators and also in their physiological functions

Mast cell subtypes
Mast cell-derived proteases
Chymase is a neutral serine protease secreted exclusively by MCTC and it appears that chymase plays a major role in the proteolytic activation of MMP -1, -2 and -9 [59, 64, 65] as well as in the physiologic degradation of fibronectin and thrombin in tissues [66] . Chymase may also act as an angiotensin-converting enzyme [67] [68] [69] , release latent TGF-ß1 from the extracellular matrix [70] , inhibit smooth muscle growth [71] and induce apoptosis of arterial smooth muscle cells [72] and endothelial cells [73] . In addition, mast cell proteases and endotoxin synergistically activate human coronary artery endothelial cells to generate interleukin-6 and interleukin-8, which may enhance the inflammatory response in atherosclerotic lesions [74] .
Cathepsin G is an elastolytic, angiotensin II-forming serine protease that is present in the granules of human MCTC [75] . Our [79] .
Mast cells are also known to produce MMPs, notably MMP-1 [80] and MMP-9 [81, 82] [87] . TNF-␣ is known to induce either directly or indirectly endothelial dysfunction and expression of the endothelial cell adhesion molecules P-selectin, Eselectin and VCAM [88] , which are responsible for leukocyte infiltration. TNF-␣ is also known to increase endothelial permeability at very low concentrations [89, 90] , an effect that is mediated via TNF receptor 1 [91] . Interestingly, the TNF-␣-mediated endothelial effects may be potentiated by interferon (IFN)-␥ [92] , a cytokine also found in atherosclerotic lesions. [86] . [93] . The activated mast cells also secrete IL-10 and TGF-␤, which are known to attenuate the inflammatory response in the atherosclerotic lesions [94] . In addition to releasing cytokines, the activated mast cells are able to secrete both ␣-chemokines (CXCL1, CXCL2, CXCL8, CXCL9, CXCL10, CXCL11) and ␤-chemokines (CCL2, CCL3, CCL4, CCL5, CCL11, CCL20) that recruit additional effector cells and regulate immune responses [29, 86, 95] .
Newly formed cytokines and chemokines
Upon activation, mast cells produce a plethora of different cytokines and chemokines that may actively participate in the pathogenesis of the atherosclerotic plaques. These include at least the following: TNF-␣, IFN-␣, IFN-␤, IL-1␣ IL-1␤, IL-6, IL-18, granulocyte macrophage-colony stimulating factor (GM-CSF), and leukaemia inhibitory factor (LIF), all of which are involved in the induction of inflammation
Furthermore, mast cells also secrete cytokines that are capable of inducing either T helper 1-type (Th1) polarization (IL-12 and IFN-␥) or T helper 2-type (Th2) polarization (IL-3, IL-4, IL-5, IL-9, IL-13, IL-15 and IL-16)
Newly formed lipid mediators
Activated mast cells also mobilize arachidonic acid through the activation of cytosolic phospholipase A2, with ensuing rapid generation and secretion of both prostaglandin D2 and leukotriene C4 [96] . The mast cell-derived eicosanoids interact with their respective cellular receptors and are known to serve diverse functions in vasoconstriction, cell trafficking, antigen presentation, immune cell activation, matrix deposition and fibrosis [96] . Interestingly, atherosclerotic arteries are hyperresponsive to the constricting effects of leukotrienes [97] , whereas prostanoids, by being important mediators of inflammation and endothelial dysfunction are also likely to contribute to the hyperresponsiveness of the endothelium in atherosclerosis lesions [98] . [133] . [7] . In contrast, a Th1-type polarization, involving high expression of IFN-␥ is inhibitory for human mast cell growth and differentiation [134] . Since atherosclerosis is generally considered to be a Th1-driven disease, which at the early stages of fatty streak formation may be counteracted by Th2-mechanisms [135] , the role of mast cells may change with the progression of the disease. Indeed, in advanced stages of atherosclerosis, the Th2-driven processes might also be proatherosclerotic [136, 137] [138] , and especially in terms of mast cell proliferation and differentiation. [142] , and IL-17, the main mediator of Th17-driven inflammation, is induced in unstable angina and acute myocardial infarction [143] . [144] , induction of smooth muscle cell death [72, 145] , induction of death [73] or detachment of vulnerable endothelial cells [76] , and triggering coronary artery spasm [41, 102, 146] (Fig. 3) .
Mast cells in the vessel wall
Mast cell -an inflammatory cell
Due to their strategic localization in the close vicinity of endothelial cells, mast cells are involved in the regulation of innate and acquired immune responses, such as the infiltration of T-cells, macrophages and neutrophils [23, 86]. In human atherosclerotic plaques, T-cells co-localize with mast cells, suggesting a close interaction between these cell types. The direct contact between the two cell types may not only influence the functions of the individual cells, but may exert a more general immunoregulatory function that affects their microenvironment [128-130]. For instance, inflammatory areas of ruptured human atherosclerotic plaques have been shown to contain CD30 [131], and CD30-CD30L interaction is known to induce degranulation-independent secretion of chemokines by mast cells [127]. In addition, mast cells may activate T-cells by releasing TNF-␣ [132] and by expressing the costimulatory OX40L, which induces a direct cell-cell interaction between mast cells and the OX40 receptor on T-cells
How could the Th1/Th2 polarization in atherosclerotic lesions affect the local development and activation of mast cells? Since human mast cells obey SCF-dependent, cytokine-driven (IL-3, IL-5, IL-6, IL-9 and granulocyte/macrophage colony-stimulating factor) mitogenic responses, and since they have a unique profile of chemokine receptors (e.g. CCR3), an increased infiltration and differentiation of mast cells reflects a Th2-type polarization
Mast cells also induce infiltration of monocytes and neutrophils [139] by secreting various chemokines, such as MCP-1 and IL-8. The participation of monocyte/macrophages in plaque remodeling that pre-dispose to rupture is well established [140]. In addition, the mast cell-dependent recruitment of neutrophils may be of special importance in the infarct-related coronary plaques, which, in contrast to the more innocent stable plaques, often contain neutrophils [141]. Indeed, mast cells participate in the induction of antigen-and Th17 cell-dependent neutrophil-rich inflammatory responses
Coronary mast cells in acute human myocardial infarction
By pre-disposing atherosclerotic plaques to erosion and rupture, mast cells are thought to contribute actively to acute coronary syndromes, including myocardial infarction. The mechanisms by which mast cells may induce atherothrombotic events include adverse remodeling of the atherosclerotic plaque
The number of plaque erosions and the proportion of mast cells associated with erosions increases markedly as the disease becomes more severe [76] . [150] [151] [152] . [124] , and so participate in events leading to plaque erosion and rupture. Indeed, histamine released from activated adventitial mast cells may reach the media, where it could act on smooth muscle cells, and by provoking a local spasm, histamine could contribute to the onset of acute cardiac events [146, 153] . Interestingly, the proportion of activated and degranulated adventitial mast cells was found to be highest in the segments with ruptured plaques [102] [154] . Although some studies have shown that artificial induction of neointima by ligation of the common carotid artery [155] , by non-constrictive cuffing of the femoral artery [156] , or by a combination of both [157, 158] [159] . According to these data, the ruptured plaques show many of the characteristics of vulnerable plaques in human beings [159] , and the ruptures can be prevented by statin treatment [160] . Thus [161, 162] , and that observations made in such animal models may not truly reflect the human disease. Indeed, one of [163, 164] , that may activate the adventitial mast cells. In addition, recent data show that activation of adventitial mast cells promote atherogenesis and induce plaque destabilization in apoE-deficient mice [165] . A targeted activation of adventitial mast cells in advanced carotid atherosclerotic plaques sharply increases the incidence of intraplaque haemorrhage, macrophage apoptosis, vascular leakage and CXCR2/VLA-4-mediated recruitment of leukocytes to the plaque [165] .
Mast cells are also known to cause endothelial dysfunction and activation of endothelial adhesion molecules [30], effects that also may pre-dispose to plaque erosion and rupture. Mast cell-derived histamine increases the permeability of EC by binding to histamine receptors (H1 receptors) on the endothelial cell surface so increasing phosphorylation of adherent junction molecules and loosening of vascular endothelial (VE)-cadherin-mediated endothelial cell-cell adhesions [147-149]. PAR-2 cleavage and activation by mast cell-derived tryptase, chymase and cathepsin G may also induce loosening of VEcadherin-mediated cell-cell adhesions
Activation of adventitial mast cells by nervous stimuli may regulate vessel tone and also various functions of vasa vasorum
Fig. 3 Activated mast cells may contribute to plaque erosion and rupture. The number of activated intimal and adventitial mast cells is increased in atherosclerotic plaques. Two types of plaques are shown: (1) a stenotic plaque with a thick fibrous cap and a small necrotic lipid core (left), and (2) a non-stenotic plaque with a thin fibrous cap and a large lipid core (right). The stenotic plaque is prone to erosion and the non-stenotic plaque is prone to rupture. Activated mast cells secrete cytokines and chemokines that regulate innate and acquired immune responses. Mast cells also secrete neutral serine proteases and MMPs that may degrade the components of the pericellular and extracellular matrices, and also the internal elastic lamina. Proteolytic degradation of collagen, elastin and proteoglycan-containing matrices weakens the fibrous cap and renders the plaque susceptible to erosion and rupture. Mast cells, as a source of proangiogenic growth factors and proteases may also induce the formation of neovessels that traverse the medial layer into the intima and weaken
Clinical approaches to stabilize mast cells in the atherosclerotic plaque
Pathological vasoconstriction or spasm of inflamed atherosclerotic coronary segments plays an important role in acute coronary syndromes and has also been suggested to pre-dispose to plaque rupture and erosion [41, 166, 167] . Since mast cell-derived histamine and leukotrienes have been suggested to trigger coronary spasm [124, 146] and since both antihistamines and leukotriene receptor antagonists are available for human use [168] , clinical studies regarding their use in the treatment of atherosclerosis may be feasible in the future [169] . Interestingly, an H1-antihistamine (desloratadine) has been shown to inhibit mast cell activation in vitro [170] and simultaneous inhibition of H1 and H2 receptors may be even more efficient in mast cell stabilization than inhibition of either receptor alone [171] [180] . PDE5 inhibitors were tested also for treatment of angina pectoris, but proved not to have any beneficial effect over nitrates [181] . Since SCF is necessary for mast cell development, proliferation and survival, and participates in homing and adhesion of mast cells, it may also be a target of therapy [182] [184] . In addition, recent results have shown that cerivastatin and atorvastatin, and partially also lovastatin act as inhibitors of growth and function of human mast cells [185] . However, simvastatin and pravastatin did not affect mediator release or growth of human mast cells, revealing that the inhibitory effects were not a class effect, but peculiarly specific for particular statins [185] .
Conclusions
Accumulating evidence clearly suggests a role for mast cells in the pathogenesis of plaque erosion and rupture [144] (Fig. 3) 
